Natalie Dayneka
Dr. Natalie Dayneka is a Canadian clinical paediatric pharmacist based in Ottawa, Ontario. She is notable during the COVID-19 pandemic due to her role in approving COVID-19 vaccines while serving on the National Advisory Committee on Immunization (NACI).1)
Career
Dayneka has worked as a pharmacist in several locations including Churchill, Manitoba, Philadelphia, and at SickKids in Toronto, Ontario.2)
She has published research on behalf of the Department of Pharmaceutics at the State University of New York School of Pharmacy and the Philadelphia College of Pharmacy and Science.3)
Dayneka is a clinical specialist with the Pharmacy Department of the tertiary care pediatric teaching hospital Children's Hospital of Eastern Ontario (CHEO).4) She was a co-author of the online 2015 CHEO Antimicrobial Guidelines for Children which has been offered externally as a mobile application (APP) for pediatric practitioners across Canada.
She has consulted on various federal committees and was a member of the Pharmacology and Therapeutics Committee for the First Nations and Inuit Health Programs Directorate. She also served on the Canadian Paediatric Society's Drug Therapy and Hazardous Substances Committee. CPS receives funding through sponsorships by Abbott, AstraZeneca, Canadian Institutes for Health Research, Elvium Life Sciences, GlaxoSmithKline, Johnson & Johnson, Medexus Pharma, Merck, Pendopharm, Pfizer, Sanofi Genzyme, and UltraGenyx.5)
More recently, she served on the Ontario Quality Based Procedure Tonsillectomy Clinical Expert Advisory Group.6)
Canadian Society of Hospital Pharmacists
Dayneka is a Fellow of the Canadian Society of Hospital Pharmacists (CSHP).7) The CSHP receives funding through sponsorships and foundation donations from Accel Pharma, Amgen, Apotex, Astellas, AstraZeneca, Canadian Pharmaceutical Distribution Network, Fresenius Kabi, HealthPro, Janssen, Knight Therapeutics, LEO Pharma, Marcan Pharmaceuticals, Omega, Otsuka, Pfizer, Pharmascience, Sandoz, Sanofi, SteriMax, Teva, and Viatris.8) 9) 10) 11) 12) 13)
Canadian HIV/AIDS Pharmacists Network
Dayneka has served as a member, Chair and Past Chair of the Canadian HIV/AIDS Pharmacists Network (CHAP) (now called the Canadian HIV and Viral Hepatitis Pharmacists Network),14) 15) 16) where she published research sponsored by Merck.17) Additional sponsors of the network during her membership include Abbott, AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Theratechnologies, and ViiV Healthcare.18) The network itself is sponsored by the Toronto General Hospital HIV Clinic, which is funded through unrestricted grants by AbbVie, Gilead Sciences and ViiV Healthcare.19)
Public Health Agency of Canada
Dayneka is employed by the Public Health Agency of Canada's Immunization Branch as a senior advisor in Causality Assessment for COVID-19 vaccine surveillance.20) 21)
National Advisory Committee on Immunization
Dayneka formerly served on the National Advisory Committee on Immunization (NACI), including as chair of the Vaccine Safety Working Group.22)
Research
Funding
In 1993, Dayneka received research funding from the National Institute of General Medicine Services (NIGMS) under the National Institutes of Health (NIH).24) She disclosed engaging in consulting activities for Gilead Sciences and Janssen.25) Further research was funded by AstraZeneca, Cook, and Covidien.26)